Skip to main content
Peter Kaiser, MD, Ophthalmology, Cleveland, OH, Cleveland Clinic

PeterKKaiserMD

Ophthalmology Cleveland, OH

Retinal Disease

Chaney Family Endowed Chair in Ophthalmology Research Professor of Ophthalmology, Cole Eye Institute, Cleveland, OH

Dr. Kaiser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kaiser's full profile

Already have an account?

Education & Training

  • Bascom Palmer Eye Institute
    Bascom Palmer Eye InstituteFellow, Clinical, 1996 - 1997
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
  • Massachusetts Eye and Ear Infirmary
    Massachusetts Eye and Ear InfirmaryClinical, Ophthalmology, 1993 - 1996
  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Internal Medicine, 1992 - 1993
  • Harvard Medical School
    Harvard Medical SchoolClass of 1992
  • Harvard College
    Harvard CollegeBachelor of Arts, 1984 - 1988

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2002 - 2026
  • MA State Medical License
    MA State Medical License 2002 - 2026
  • FL State Medical License
    FL State Medical License 2004 - 2026
  • IL State Medical License
    IL State Medical License 2002 - 2026
  • MI State Medical License
    MI State Medical License 2002 - 2026
  • CA State Medical License
    CA State Medical License 2002 - 2025
  • OH State Medical License
    OH State Medical License 1997 - 2024
  • American Board of Ophthalmology Ophthalmology
  • Join now to see all

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Lew R. Wasserman Merit Award Research to Prevent Blindness 2010
  • American Academy of Ophthalmology Senior Achievement Award (Senior Honor Award) 2008
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • HIV-1 coat protein increases intracellular Ca2+ and injures neurons: toxicity prevented by calcium channel antagonists.  
    Dreyer EB, Kaiser PK, Offermann JT, and Lipton SA., Science 1990
  • Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies.  
    Kaiser PK, Offermann JT, and Lipton SA., Neurology 1990
  • VIP-mediated increase in cAMP prevents TTX-induced retinal ganglion cell death in vitro.  
    Kaiser PK and Lipton SA., Neuron 1990
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Plasma Peptidomics for Predicting AMD Susceptibility.
    Gu J, Wu Z, Crabb JS, Gu X, Simpson E, Bala E, Sturgill G, Yaniglos S, Peachey N, Hagstrom SA, Kaiser PK, Sears JE, Lewis H, Salomon RG, and Crabb JW, Inv Ophthalmol & Vis Sci
  • OCT and Angiographic Analysis of Neovascular AMD Treated With PDT in Combination With Intravitreal Triamcinolone Acetonide vs. PDT Alone.
    Ufret-Vincenty R, Williams DR, and Kaiser PK, Inv Ophthalmol & Vis Sci
  • Microsphere Luminex Technology for the Analysis of Microliters of Vitreous Fluid.
    Bakri SJ, Bonfield, Kaiser PK, and Perez VL, Inv Ophthalmol & Vis Sci
  • Join now to see all

Lectures

  • Exudative macular degeneration therapies: PDT update. 
    Optometric Retina Society Boston, MA
  • Optical coherence tomography in pre and post-operative macular hole surgery. 
    Frankfurt Retina Meeting 2004 Frankfurt, Germany
  • Current management of submacular hemorrhage. 
    Frankfurt Retina Meeting 2004 Frankfurt, Germany
  • Join now to see all

Press Mentions

  • Cimerli Approved as Interchangeable Biosimilar to Lucentis
    Cimerli Approved as Interchangeable Biosimilar to LucentisAugust 3rd, 2022
  • FDA Approves Coherus' CIMERLI(TM) (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis(TM) for All Five Indications, with 12 Months of Interchangeability Exclusivity
    FDA Approves Coherus' CIMERLI(TM) (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis(TM) for All Five Indications, with 12 Months of Interchangeability ExclusivityAugust 2nd, 2022
  • FDA Approves Coherus’ CIMERLI™ (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
    FDA Approves Coherus’ CIMERLI™ (Ranibizumab-Eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability ExclusivityAugust 2nd, 2022
  • Join now to see all

Grant Support

  • Vacsular Remodeling And Effects Of Angiogenic Inhibition In Diabetic RetinopathyNational Eye Institute2006
  • Vascular Remodeling And Effects Of Angiogenic InhibitionNational Eye Institute2005

Professional Memberships

Hospital Affiliations